Published in Biomaterials on January 01, 2006
Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev (2009) 3.08
Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION). Nano Rev (2010) 1.88
Differential proteomics analysis of the surface heterogeneity of dextran iron oxide nanoparticles and the implications for their in vivo clearance. Biomaterials (2009) 1.19
Convection-enhanced delivery of maghemite nanoparticles: Increased efficacy and MRI monitoring. Neuro Oncol (2008) 1.14
Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases. Int J Nanomedicine (2008) 1.09
Biological properties of iron oxide nanoparticles for cellular and molecular magnetic resonance imaging. Int J Mol Sci (2010) 1.02
Problems and challenges in the development and validation of human cell-based assays to determine nanoparticle-induced immunomodulatory effects. Part Fibre Toxicol (2011) 1.02
Stealth properties to improve therapeutic efficacy of drug nanocarriers. J Drug Deliv (2013) 0.99
Cell-based in vitro blood-brain barrier model can rapidly evaluate nanoparticles' brain permeability in association with particle size and surface modification. Int J Mol Sci (2014) 0.91
Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo. Nat Nanotechnol (2016) 0.91
Cellular Uptake and Intracellular Cargo Release From Dextran Based Nanogel Drug Carriers. J Nanotechnol Eng Med (2013) 0.85
Analytical strategies for detecting nanoparticle-protein interactions. Analyst (2010) 0.85
Effect of the protein corona on nanoparticles for modulating cytotoxicity and immunotoxicity. Int J Nanomedicine (2014) 0.83
Protein corona - from molecular adsorption to physiological complexity. Beilstein J Nanotechnol (2015) 0.82
Biocompatible ι-carrageenan-γ-maghemite nanocomposite for biomedical applications - synthesis, characterization and in vitro anticancer efficacy. J Nanobiotechnology (2015) 0.81
Cationic antimicrobial peptides and biogenic silver nanoparticles kill mycobacteria without eliciting DNA damage and cytotoxicity in mouse macrophages. Antimicrob Agents Chemother (2013) 0.80
Application of polysaccharides for surface modification of nanomedicines. Ther Deliv (2012) 0.77
Activation of Human Complement System by Dextran-Coated Iron Oxide Nanoparticles Is Not Affected by Dextran/Fe Ratio, Hydroxyl Modifications, and Crosslinking. Front Immunol (2016) 0.77
Self-assembled polymeric nanoparticles based on oleic acid-grafted chitosan oligosaccharide: biocompatibility, protein adsorption and cellular uptake. J Mater Sci Mater Med (2012) 0.77
In Vitro and In Vivo Differences in Murine Third Complement Component (C3) Opsonization and Macrophage/Leukocyte Responses to Antibody-Functionalized Iron Oxide Nanoworms. Front Immunol (2017) 0.75
Antiproliferative activity of fucan nanogel. Mar Drugs (2012) 0.75
Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev (2002) 7.05
Stimuli-responsive nanocarriers for drug delivery. Nat Mater (2013) 3.52
Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci (2009) 2.63
Porous metal-organic-framework nanoscale carriers as a potential platform for drug delivery and imaging. Nat Mater (2009) 2.43
Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials (2008) 2.43
Magnetic nanoparticles: design and characterization, toxicity and biocompatibility, pharmaceutical and biomedical applications. Chem Rev (2012) 2.26
Folate-conjugated iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: synthesis, physicochemical characterization, and in vitro experiments. Bioconjug Chem (2005) 1.99
Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials (2006) 1.94
Metal-organic frameworks in biomedicine. Chem Rev (2011) 1.93
Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials (2009) 1.59
Spatiotemporal control of endocytosis by phosphatidylinositol-3,4-bisphosphate. Nature (2013) 1.59
Influence of surface charge density on protein adsorption on polymeric nanoparticles: analysis by two-dimensional electrophoresis. Eur J Pharm Biopharm (2002) 1.55
Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery. Chem Soc Rev (2013) 1.43
Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J Hepatol (2005) 1.38
Structure and function of a mitochondrial late embryogenesis abundant protein are revealed by desiccation. Plant Cell (2007) 1.34
The promotion of oriented axonal regrowth in the injured spinal cord by alginate-based anisotropic capillary hydrogels. Biomaterials (2006) 1.30
Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv Drug Deliv Rev (2003) 1.25
Squalene: A natural triterpene for use in disease management and therapy. Adv Drug Deliv Rev (2009) 1.25
Physicochemical characterization of ultrasmall superparamagnetic iron oxide particles (USPIO) for biomedical application as MRI contrast agents. Int J Nanomedicine (2007) 1.21
Nanotheranostics for personalized medicine. Adv Drug Deliv Rev (2012) 1.19
BioMOFs: metal-organic frameworks for biological and medical applications. Angew Chem Int Ed Engl (2010) 1.16
Surface-engineered nanoparticles for multiple ligand coupling. Biomaterials (2003) 1.15
Interactions of blood proteins with poly(isobutylcyanoacrylate) nanoparticles decorated with a polysaccharidic brush. Biomaterials (2005) 1.14
The effect of a PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa. Eur J Pharm Sci (2003) 1.13
Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting. J Pharmacol Exp Ther (2002) 1.12
Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine (Lond) (2010) 1.10
Polysaccharide-decorated nanoparticles. Eur J Pharm Biopharm (2004) 1.08
A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types. J Control Release (2007) 1.06
Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjug Chem (2005) 1.03
A prospective study on radiation-induced changes in hearing function. Int J Radiat Oncol Biol Phys (2006) 1.03
Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting. Biomaterials (2009) 1.02
The importance of the stem cell marker prominin-1/CD133 in the uptake of transferrin and in iron metabolism in human colon cancer Caco-2 cells. PLoS One (2011) 1.02
Mesenchymal stem cells as cellular vehicles for delivery of nanoparticles to brain tumors. Biomaterials (2010) 1.01
"Smart" delivery of antisense oligonucleotides by anionic pH-sensitive liposomes. Adv Drug Deliv Rev (2004) 1.01
Metallic colloid nanotechnology, applications in diagnosis and therapeutics. Curr Pharm Des (2005) 1.01
A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection. J Neurosci (2009) 1.01
Passive and active tumour targeting with nanocarriers. Curr Drug Discov Technol (2011) 1.00
Analysis of plasma protein adsorption onto PEGylated nanoparticles by complementary methods: 2-DE, CE and Protein Lab-on-chip system. Electrophoresis (2007) 1.00
A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic long-circulating properties and anticancer activity. Proc Natl Acad Sci U S A (2014) 1.00
Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer. Nanomedicine (2011) 0.99
The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting. Nanomedicine (Lond) (2010) 0.99
Novel approaches to deliver gemcitabine to cancers. Curr Pharm Des (2008) 0.99
Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues. Nanomedicine (2011) 0.98
Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. Eur J Immunol (2004) 0.98
Negative preclinical results with stealth nanospheres-encapsulated Doxorubicin in an orthotopic murine brain tumor model. J Control Release (2004) 0.98
Synthesis and biological evaluation of folate receptor-targeted boronated PAMAM dendrimers as potential agents for neutron capture therapy. Bioconjug Chem (2003) 0.98
Encapsulation of gemcitabine lipophilic derivatives into polycyanoacrylate nanospheres and nanocapsules. Int J Pharm (2007) 0.98
Lipid conjugated oligonucleotides: a useful strategy for delivery. Bioconjug Chem (2012) 0.97
Efficacy of siRNA nanocapsules targeted against the EWS-Fli1 oncogene in Ewing sarcoma. Pharm Res (2006) 0.96
A review of the current status of siRNA nanomedicines in the treatment of cancer. Biomaterials (2013) 0.95
Magnetoresponsive squalenoyl gemcitabine composite nanoparticles for cancer active targeting. Langmuir (2008) 0.95
Polymeric nanoparticulate system augmented the anticancer therapeutic efficacy of gemcitabine. J Drug Target (2009) 0.95
Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat. Eur J Neurosci (2002) 0.95
Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor. Int J Pharm (2005) 0.95
Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics. ACS Nano (2011) 0.94
Role of gut macrophages in mice orally contaminated with scrapie or BSE. Int J Pharm (2005) 0.93
The extracellular matrix glycoprotein Tenascin-C is expressed by oligodendrocyte precursor cells and required for the regulation of maturation rate, survival and responsiveness to platelet-derived growth factor. Eur J Neurosci (2004) 0.92
Translocation of poly(ethylene glycol-co-hexadecyl)cyanoacrylate nanoparticles into rat brain endothelial cells: role of apolipoproteins in receptor-mediated endocytosis. Biomacromolecules (2007) 0.92
The potential of combinations of drug-loaded nanoparticle systems and adult stem cells for glioma therapy. Biomaterials (2010) 0.92
Activation of membrane-permeant caged PtdIns(3)P induces endosomal fusion in cells. Nat Chem Biol (2010) 0.92
Influence of polymer behaviour in organic solution on the production of polylactide nanoparticles by nanoprecipitation. Int J Pharm (2007) 0.91
Non-viral nanosystems for systemic siRNA delivery. Pharmacol Res (2009) 0.91
Versatile and efficient targeting using a single nanoparticulate platform: application to cancer and Alzheimer's disease. ACS Nano (2012) 0.91
Study of emulsion stabilization by graft copolymers using the optical analyzer Turbiscan. Int J Pharm (2003) 0.90
Influence of size, surface coating and fine chemical composition on the in vitro reactivity and in vivo biodistribution of lipid nanocapsules versus lipid nanoemulsions in cancer models. Nanomedicine (2012) 0.90
Self-assembled multicompartment liquid crystalline lipid carriers for protein, peptide, and nucleic acid drug delivery. Acc Chem Res (2010) 0.90
Tumor transfection after systemic injection of DNA lipid nanocapsules. Biomaterials (2010) 0.90
Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. Invest Ophthalmol Vis Sci (2002) 0.90
Synthesis, characterization, and in vivo delivery of siRNA-squalene nanoparticles targeting fusion oncogene in papillary thyroid carcinoma. J Med Chem (2011) 0.90
Colloidal stability of ultrasmall superparamagnetic iron oxide (USPIO) particles with different coatings. Int J Pharm (2006) 0.90
The importance of endo-lysosomal escape with lipid nanocapsules for drug subcellular bioavailability. Biomaterials (2010) 0.90
The encapsulation of DNA molecules within biomimetic lipid nanocapsules. Biomaterials (2009) 0.89
Serum-stable and long-circulating, PEGylated, pH-sensitive liposomes. J Control Release (2004) 0.89
The dose-response relationship and regional distribution of lactate after intramuscular injection of halothane and caffeine in malignant hyperthermia-susceptible pigs. Anesth Analg (2006) 0.89
In vivo evaluation of intracellular drug-nanocarriers infused into intracranial tumours by convection-enhanced delivery: distribution and radiosensitisation efficacy. J Neurooncol (2009) 0.89
Colon-specific 9-aminocamptothecin-HPMA copolymer conjugates containing a 1,6-elimination spacer. J Control Release (2005) 0.89
Preclinical toxicology (subacute and acute) and efficacy of a new squalenoyl gemcitabine anticancer nanomedicine. J Pharmacol Exp Ther (2008) 0.89
Squalenoylation favorably modifies the in vivo pharmacokinetics and biodistribution of gemcitabine in mice. Drug Metab Dispos (2008) 0.88
Squalenoylation: a generic platform for nanoparticular drug delivery. J Control Release (2011) 0.88
Transferrin adsorption onto PLGA nanoparticles governs their interaction with biological systems from blood circulation to brain cancer cells. Pharm Res (2011) 0.88
Novel polysaccharide-decorated poly(isobutyl cyanoacrylate) nanoparticles. Pharm Res (2003) 0.88
Cationic vectors in ocular drug delivery. J Drug Target (2004) 0.87
Anticancer efficacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumor. Mol Pharm (2009) 0.87
A methodology to study intracellular distribution of nanoparticles in brain endothelial cells. Int J Pharm (2005) 0.87
PEGylated nanoparticles bind to and alter amyloid-beta peptide conformation: toward engineering of functional nanomedicines for Alzheimer's disease. ACS Nano (2012) 0.86
Electrokinetic properties of noncharged lipid nanocapsules: influence of the dipolar distribution at the interface. Electrophoresis (2005) 0.86
Prediction of outcome in neurogenic oropharyngeal dysphagia within 72 hours of acute stroke. J Stroke Cerebrovasc Dis (2011) 0.86
Design of fluorescently tagged poly(alkyl cyanoacrylate) nanoparticles for human brain endothelial cell imaging. Chem Commun (Camb) (2010) 0.86
Tumor eradication in rat glioma and bypass of immunosuppressive barriers using internal radiation with (188)Re-lipid nanocapsules. Biomaterials (2011) 0.85